A Phase II Study of Ibrutinib plus Rituximab with Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy before Chemotherapy
MD Anderson Study Status
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate
This phase II trial studies how well ibrutinib, rituximab, and consolidation chemotherapy consisting of cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine work in treating young patients with newly diagnosed mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving ibrutinib together with rituximab and consolidation chemotherapy may be a better treatment for mantle cell lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Blastoid Variant Mantle Cell Lymphoma, CD20 Positive, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.